BR112014028951A2 - peptídeos ledgf e formulações dos mesmos para tratamento de distúrbios degenerativos - Google Patents
peptídeos ledgf e formulações dos mesmos para tratamento de distúrbios degenerativosInfo
- Publication number
- BR112014028951A2 BR112014028951A2 BR112014028951A BR112014028951A BR112014028951A2 BR 112014028951 A2 BR112014028951 A2 BR 112014028951A2 BR 112014028951 A BR112014028951 A BR 112014028951A BR 112014028951 A BR112014028951 A BR 112014028951A BR 112014028951 A2 BR112014028951 A2 BR 112014028951A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulations
- ledgf peptides
- degenerative disorders
- ledgf
- peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
resumo patente de invenção: peptídeos ledgf e formulações dos mesmos para tratamento de distúrbios degenerativos. a presente invenção refere-se aos peptídeos de ledgf com atividade de agregação antiproteína e métodos de uso. os peptídeos de ledgf descritos aqui demonstram uma capacidade para tratar doenças degenerativas e doenças com vários estresses celulares, incluindo estresse oxidativo e estresse de proteína-agregação. em adição, formulações de liberação prolongada, incluindo formulações apropriadas para administração oftálmica são providas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261649847P | 2012-05-21 | 2012-05-21 | |
PCT/US2012/065620 WO2013074988A1 (en) | 2011-11-17 | 2012-11-16 | Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations |
PCT/US2013/042074 WO2013177198A1 (en) | 2012-05-21 | 2013-05-21 | Ledgf peptides and formulations thereof for treatment of degenerative disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014028951A2 true BR112014028951A2 (pt) | 2017-07-25 |
BR112014028951A8 BR112014028951A8 (pt) | 2021-09-14 |
Family
ID=49624295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014028951A BR112014028951A8 (pt) | 2012-05-21 | 2013-05-21 | Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor |
Country Status (12)
Country | Link |
---|---|
US (2) | US9526760B2 (pt) |
EP (1) | EP2852399B1 (pt) |
JP (2) | JP6632376B2 (pt) |
CN (2) | CN110054677A (pt) |
AU (1) | AU2013266468B2 (pt) |
BR (1) | BR112014028951A8 (pt) |
CA (1) | CA2873771A1 (pt) |
DK (1) | DK2852399T3 (pt) |
ES (1) | ES2791251T3 (pt) |
IN (1) | IN2014MN02461A (pt) |
RU (1) | RU2617964C2 (pt) |
WO (1) | WO2013177198A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9526760B2 (en) * | 2012-05-21 | 2016-12-27 | The Regents Of The University Of Colorado, A Body Corporate | LEDGF peptides and formulations thereof for treatment of degenerative disorders |
KR101748120B1 (ko) * | 2015-07-13 | 2017-06-16 | 서울대학교산학협력단 | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
US20180207293A1 (en) * | 2017-01-25 | 2018-07-26 | 2C Tech Corp. | Nanoparticles for sustained ophthalmic drug delivery and methods of use |
CN112601541A (zh) * | 2018-06-22 | 2021-04-02 | 比欧拉利克斯有限公司 | 口服给药的生物聚合物制剂 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4221787A (en) | 1978-03-28 | 1980-09-09 | Interx Research Corporation | Esteramide prodrugs of anti-inflammatory corticosteroids |
US4469689A (en) | 1983-03-30 | 1984-09-04 | The Upjohn Company | Sulfonate containing ester prodrugs of corticosteroids |
US6750052B1 (en) | 1997-07-23 | 2004-06-15 | The Brigham And Women's Hospital, Inc. | Lens epithelial cell derived growth factor |
US7708915B2 (en) * | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
EP1562627A4 (en) | 2002-08-23 | 2006-11-02 | Mclean Hospital Corp | CORTICOSTEROID CONJUGATES AND ITS USES |
AU2003273633A1 (en) * | 2002-09-26 | 2004-04-19 | K.U.Leuven Research And Development | Integrase cofactor |
AU2003298786A1 (en) * | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
US20060166879A1 (en) * | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
US8999633B2 (en) * | 2004-05-28 | 2015-04-07 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans |
ES2406716T3 (es) | 2005-12-30 | 2013-06-07 | Neurotech Usa, Inc. | Dispositivo micronizado para el suministro de moléculas activas biológicamente y método de uso del mismo |
JP5244103B2 (ja) * | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
WO2008053478A2 (en) * | 2006-10-30 | 2008-05-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for inhibiting hiv-1 replication and integrase activity |
US8168393B2 (en) * | 2007-02-16 | 2012-05-01 | The Brigham And Women's Hospital, Inc. | Compositions and methods for diagnosing tumors using LEDGF/p75 |
WO2009155936A1 (en) * | 2008-06-26 | 2009-12-30 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
GB0812742D0 (en) * | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
WO2013006156A1 (en) * | 2011-07-01 | 2013-01-10 | Inova Diagnostics, Inc. | Method for increasing specificity of diagnostic tests for autoimmune diseases |
US9526760B2 (en) * | 2012-05-21 | 2016-12-27 | The Regents Of The University Of Colorado, A Body Corporate | LEDGF peptides and formulations thereof for treatment of degenerative disorders |
-
2013
- 2013-05-21 US US14/402,426 patent/US9526760B2/en active Active
- 2013-05-21 CA CA2873771A patent/CA2873771A1/en not_active Abandoned
- 2013-05-21 CN CN201811628163.9A patent/CN110054677A/zh active Pending
- 2013-05-21 IN IN2461MUN2014 patent/IN2014MN02461A/en unknown
- 2013-05-21 EP EP13794410.4A patent/EP2852399B1/en active Active
- 2013-05-21 CN CN201380038504.6A patent/CN104470534A/zh active Pending
- 2013-05-21 DK DK13794410.4T patent/DK2852399T3/da active
- 2013-05-21 WO PCT/US2013/042074 patent/WO2013177198A1/en active Application Filing
- 2013-05-21 BR BR112014028951A patent/BR112014028951A8/pt not_active IP Right Cessation
- 2013-05-21 RU RU2014151603A patent/RU2617964C2/ru active
- 2013-05-21 JP JP2015514127A patent/JP6632376B2/ja not_active Expired - Fee Related
- 2013-05-21 ES ES13794410T patent/ES2791251T3/es active Active
- 2013-05-21 AU AU2013266468A patent/AU2013266468B2/en active Active
-
2016
- 2016-11-10 US US15/348,970 patent/US10221226B2/en active Active
-
2018
- 2018-05-23 JP JP2018098420A patent/JP2018172386A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US9526760B2 (en) | 2016-12-27 |
EP2852399A1 (en) | 2015-04-01 |
US20170129929A1 (en) | 2017-05-11 |
US20150147404A1 (en) | 2015-05-28 |
JP2015519343A (ja) | 2015-07-09 |
JP2018172386A (ja) | 2018-11-08 |
IN2014MN02461A (pt) | 2015-07-10 |
WO2013177198A1 (en) | 2013-11-28 |
DK2852399T3 (da) | 2020-05-04 |
EP2852399B1 (en) | 2020-02-19 |
CN110054677A (zh) | 2019-07-26 |
AU2013266468A1 (en) | 2014-12-18 |
CN104470534A (zh) | 2015-03-25 |
AU2013266468B2 (en) | 2017-11-09 |
RU2617964C2 (ru) | 2017-04-28 |
CA2873771A1 (en) | 2013-11-28 |
BR112014028951A8 (pt) | 2021-09-14 |
RU2014151603A (ru) | 2016-07-10 |
ES2791251T3 (es) | 2020-11-03 |
EP2852399A4 (en) | 2016-03-23 |
US10221226B2 (en) | 2019-03-05 |
JP6632376B2 (ja) | 2020-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502269A1 (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
EA201590663A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
BR112014016165A8 (pt) | compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido | |
BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
BR112013013167A8 (pt) | inibidores de bromodomínio e usos dos mesmos | |
BR112015006828A8 (pt) | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 | |
BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
BR112014017780A8 (pt) | Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos | |
BR112014007223A2 (pt) | derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos | |
EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
CU20140012A7 (es) | 3-(bifenil-3-il) -4- hidroxi-8- metoxi-1- azaespiro [4.5] dec- 3- en -2- onas sustituidas | |
UY33219A (es) | Cetoenoles cíclicos para terapias | |
WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
WO2015023553A3 (en) | Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules | |
UY34896A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
BR112014028951A2 (pt) | peptídeos ledgf e formulações dos mesmos para tratamento de distúrbios degenerativos | |
AU2012280776B2 (en) | Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases | |
BR112014015578A2 (pt) | composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide | |
EA201592242A1 (ru) | Производные пиридона для лечения вирусных инфекций и других заболеваний | |
BR112015007095A8 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2671 DE 15-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |